The Avandia (rosiglitazone) debate will heat up again now that FDA will loosen its restrictions

The Avandia (rosiglitazone) debate will heat up again now that FDA will loosen its restrictions.

This decision is based on a reanalysis of an older study that suggests Avandia DOES NOT increase cardiovascular risk.

But experts warn that reanalyzing a flawed study doesn't make it valid...and other studies DO suggest Avandia increases CV risk.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote